Memorial Sloan Kettering Cancer Center
- Country
- πΊπΈUnited States
- Ownership
- Private
- Established
- 1884-01-01
- Employees
- 10K
- Market Cap
- -
- Website
- http://www.mskcc.org
A Study of Epacadostat, an IDO1 Inhibitor, in Combination With Pembrolizumab in Patients With Metastatic and/or Locally Advanced Sarcoma
- First Posted Date
- 2018-01-29
- Last Posted Date
- 2025-05-02
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 30
- Registration Number
- NCT03414229
- Locations
- πΊπΈ
Memorial Sloan Kettering Cancer Center, New York, New York, United States
A Phase II Study of the BRAF Inhibitor, Vemurafenib, Plus Obinutuzumab in Patients With Previously Untreated Classical Hairy Cell Leukemia
- Conditions
- Hairy Cell LeukemiaLeukemiaLeukemia, Hairy Cell
- Interventions
- First Posted Date
- 2018-01-25
- Last Posted Date
- 2025-02-11
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 30
- Registration Number
- NCT03410875
- Locations
- πΊπΈ
Memorial Sloan Kettering at Basking Ridge, Basking Ridge, New Jersey, United States
πΊπΈMemorial Sloan Kettering Cancer Center @ Commack (Limited Protocol Activities), Commack, New York, United States
πΊπΈDana Farber Cancer Institute, Boston, Massachusetts, United States
A Study Assessing Circulation Around Surgical Incisions at the Time of Laparotomy Closure
- Conditions
- Laparotomy
- Interventions
- Procedure: LaparotomyOther: ICGOther: Spectrum NIR imaging system
- First Posted Date
- 2018-01-24
- Last Posted Date
- 2022-08-02
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 20
- Registration Number
- NCT03408366
- Locations
- πΊπΈ
Memoral Sloan Kettering Monmouth (Consent only), Middletown, New Jersey, United States
πΊπΈMemoral Sloan Kettering Basking Ridge (Consent only), Basking Ridge, New Jersey, United States
πΊπΈMemorial Sloan Kettering Bergen (Consent only ), Montvale, New Jersey, United States
Stereotactic Body Radiation Therapy and Avelumab Immunotherapy for Treatment of Malignant Mesothelioma
- Conditions
- Malignant Mesothelioma (MPM)
- Interventions
- Radiation: Stereotactic Body Radiation Therapy
- First Posted Date
- 2018-01-16
- Last Posted Date
- 2023-10-23
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 15
- Registration Number
- NCT03399552
- Locations
- πΊπΈ
Memorial Sloan Kettering Commack, Commack, New York, United States
πΊπΈMemorial Sloan Kettering Westchester, Harrison, New York, United States
πΊπΈMemorial Sloan Kettering at Basking Ridge, Basking Ridge, New Jersey, United States
Responses to Genetic Risk Modifier Testing Among Women With BRCA1/2 Mutations
- Conditions
- BRCA1/2Genetic Testing
- Interventions
- Other: Salvia sampleBehavioral: Questionnaires
- First Posted Date
- 2018-01-10
- Last Posted Date
- 2025-02-07
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 350
- Registration Number
- NCT03396341
- Locations
- πΊπΈ
Dana Farber Cancer Institute (Data Collection Only), Boston, Massachusetts, United States
πΊπΈMemorial Sloan-Kettering at Basking Ridge, Basking Ridge, New Jersey, United States
πΊπΈMemorial Sloan Kettering Commack, Commack, New York, United States
Capecitabine 7/7 Schedule With Neratinib in Patients With Metastatic HER2-Positive Breast Cancer
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2017-12-19
- Last Posted Date
- 2025-04-15
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 34
- Registration Number
- NCT03377387
- Locations
- πΊπΈ
Memorial Sloan Kettering Bergen, Montvale, New Jersey, United States
πΊπΈHartford Healthcare Cancer Institute @ Hartford Hospital, Hartford, Connecticut, United States
πΊπΈBaptist Alliance - McI, Miami, Florida, United States
Development Of A Blood Test To Improve The Performance Of Breast Cancer Screening
- Conditions
- Breast CancerBreast Benign
- Interventions
- Device: Breast MRIDevice: Breast MammogramOther: Blood drawProcedure: Breast BiopsyBehavioral: online participant reported questionnaire
- First Posted Date
- 2017-12-14
- Last Posted Date
- 2025-03-14
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 628
- Registration Number
- NCT03372902
- Locations
- πΊπΈ
Hartford Healthcare Cancer Institute @ Hartford Hospital, Hartford, Connecticut, United States
πΊπΈMemorial Sloan Kettering Cancer Center, New York, New York, United States
πΊπΈBaptist Alliance MCI, Miami, Florida, United States
Collecting Information About Treatment Results for Patients With Cushing's Syndrome
- Conditions
- Cushing's DiseaseCushing SyndromeCushing Disease
- Interventions
- Other: Cushing's QoL (Quality of Life Questionnaire)Other: Nottingham Health Profile (NHP)Other: Hospital Anxiety and Depression Scale (HADS)Other: Perceived Stress Scale (PSS)Other: Barratt's Impulsivity Scale (BIS)Other: Beck Depression Inventory (BDI)Other: State-Trait Anxiety Inventory (STAI)Other: State Food Craving Questionnaire-State (FCQ-S)Other: Trait Food Craving Questionnaire-Trait (FCQ-T)Other: Visual Analogue Scale (VAS)Other: Sensitivity to Reinforcement of Addictive and other Primary Rewards (STRAP-R) food variant
- First Posted Date
- 2017-12-07
- Last Posted Date
- 2025-02-26
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 200
- Registration Number
- NCT03364803
- Locations
- πΊπΈ
Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities), Basking Ridge, New Jersey, United States
πΊπΈMemorial Sloan Kettering Cancer Center @ Suffolk-Commack (Limited protocol activity), Commack, New York, United States
πΊπΈMemorial Sloan Kettering Monmouth (Limited Protocol Activities), Middletown, New Jersey, United States
A Phase I Study of Bendamustine and Melphalan Conditioning and Autologous Stem Cell Transplantation for Treatment of Multiple Myeloma and Relapsed/Refractory B-cell Lymphoma in Elderly Patients
- Conditions
- Lymphoma
- Interventions
- Procedure: Autologous Stem Cell Transplantation (ASCT)
- First Posted Date
- 2017-11-24
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 28
- Registration Number
- NCT03352765
- Locations
- πΊπΈ
Memorial Sloan Kettering Cancer Center, New York, New York, United States
BRCA Founder OutReach (BFOR) Study
- Conditions
- BRCA1 MutationBRCA2 Mutation
- Interventions
- Other: BFOR Digital Health solution/Web Portal
- First Posted Date
- 2017-11-24
- Last Posted Date
- 2025-06-03
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 5412
- Registration Number
- NCT03351803
- Locations
- πΊπΈ
University of Pennsylvania, Philadelphia, Pennsylvania, United States
πΊπΈMemorial Sloan - Kettering Cancer Center, New York, New York, United States
πΊπΈUniversity of California, Los Angeles, Los Angeles, California, United States